Table 3.
Longitudinal follow-up of a subgroup of the children.
| Baseline children Pre-HAART (n = 22) [Median (range)] |
Children at 6 months Virologically suppressive HAART [Median (range)] |
Children at 12 months Virologically suppressive HAART [Median (range)] |
|
|---|---|---|---|
| sCD14 (ng/mL) |
10438 (960–18591) |
7270 (889–15466) |
6669∗
(734–13241) |
|
β2M (μg/mL) |
4 (3–8) |
2∗
(1.7–5) |
2.5∗
(1.3–4.5) |
| hsCRP (μg/mL) |
4 (0.2–144) |
1.3 (0.2–42) |
1.6 (0.2–43) |
| MIG (pg/mL) |
5312 (1250–11245) |
1441∗
(611–11355) |
813∗
∗∗
(385–6081) |
| IP10 (pg/mL) |
5559 (1054–64710) |
6023 (1335–18749) |
4614∗
(997–16679) |
| TGF-β1 (pg/mL) |
14868 (5247–30336) |
13419 (39–23940) |
14117 (1021–18364) |
|
| |||
| CD4+ T cell count (cells/μL) |
854 (22–5915) |
1724∗
(31–6401) |
1731∗
(635–3828) |
| CD8+ T cell count (cells/μL) |
1471 (181–3128) |
1819 (25–5984) |
1785 (44–2792) |
| HIV-viral load (copies/mL blood) |
2400000 (500–360000000) |
25∗
(25–200) |
25∗
(25–320) |
HAART: highly active antiretroviral treatment.
∗For comparison with baseline values; P < 0.05.
∗∗For comparison with the 6 months' time-point; P < 0.05.
sCD14 (soluble CD14), β2M (β2-microglobulin), hsCRP (high sensitivity CRP), MIG (monokine induced IFNγ), IP10 (IFNγ-inducible protein 10), and TGF-β1 (transforming growth factor beta 1).